MX347607B - Uso de inhibidores hsp90 etiquetados. - Google Patents

Uso de inhibidores hsp90 etiquetados.

Info

Publication number
MX347607B
MX347607B MX2014000286A MX2014000286A MX347607B MX 347607 B MX347607 B MX 347607B MX 2014000286 A MX2014000286 A MX 2014000286A MX 2014000286 A MX2014000286 A MX 2014000286A MX 347607 B MX347607 B MX 347607B
Authority
MX
Mexico
Prior art keywords
hsp90
therapy
oncogenic
abundance
species
Prior art date
Application number
MX2014000286A
Other languages
English (en)
Other versions
MX2014000286A (es
Inventor
Taldone Tony
Chiosis Gabriela
L Alpaugh Mary
L Guzman Monica
Zong Hongliang
M Gomes-Dagama Erica
Original Assignee
Sloan-Kettering Institute For Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan-Kettering Institute For Cancer Res filed Critical Sloan-Kettering Institute For Cancer Res
Publication of MX2014000286A publication Critical patent/MX2014000286A/es
Publication of MX347607B publication Critical patent/MX347607B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57426—Specifically defined cancers leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invención se refiere a la abundancia de esta especie "HSP90 oncogénica" particular, que no se dictamina por la expresión HSP90 sola, predice la sensibilidad a terapia de inhibición HSP90, y de esta manera es un biomarcador para terapia de HSP90. La descripción también proporciona evidencia que identifica y mide la abundancia de esta especie HSP90 oncogénica en predicciones de tumores de respuesta a terapia HSP90. "HSP90 oncogénico" se define en la presente como la fracción HSP90 que representa una forma específica de tensión celular del complejo acompañante, que se expande y mantiene constitutivamente en el contexto de célula de tumor, y que puede ejecutar funciones necesarias para mantener el fenotipo maligno. Tales papeles no sólo son para regular el plegado de proteínas sobreexpresadas (es decir, HER2), mutadas (es decir, rnB-Raf) o quiméricas (es decir, Ber-Abl), sino también para facilitar el andamiaje y formación de complejo de moléculas involucradas en los complejos de señalización aberrantemente activados (es decir STATS, BCL6).
MX2014000286A 2011-07-08 2012-07-06 Uso de inhibidores hsp90 etiquetados. MX347607B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161506010P 2011-07-08 2011-07-08
PCT/US2012/045864 WO2013009657A1 (en) 2011-07-08 2012-07-06 Uses of labeled hsp90 inhibitors

Publications (2)

Publication Number Publication Date
MX2014000286A MX2014000286A (es) 2015-03-06
MX347607B true MX347607B (es) 2017-05-04

Family

ID=47506428

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2014000292A MX2014000292A (es) 2011-07-08 2012-07-06 Usos de inhibidores etiquetados hsp90.
MX2014000286A MX347607B (es) 2011-07-08 2012-07-06 Uso de inhibidores hsp90 etiquetados.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2014000292A MX2014000292A (es) 2011-07-08 2012-07-06 Usos de inhibidores etiquetados hsp90.

Country Status (13)

Country Link
US (4) US9555137B2 (es)
EP (3) EP3709022A1 (es)
JP (4) JP6218147B2 (es)
KR (2) KR102025142B1 (es)
CN (3) CN109374889B (es)
AU (3) AU2012282905B8 (es)
BR (1) BR112014000445A2 (es)
CA (2) CA2841173C (es)
DK (1) DK2729806T3 (es)
EA (1) EA201490230A1 (es)
ES (2) ES2766623T3 (es)
MX (2) MX2014000292A (es)
WO (2) WO2013009655A2 (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
KR102025142B1 (ko) 2011-07-08 2019-09-26 슬로안-케테링인스티튜트퍼캔서리서치 표지된 ｈｓｐ90 억제제의 용도
SI2935222T1 (sl) 2012-12-21 2019-02-28 Epizyme Inc. Inhibitorji PRMT5 in njihove uporabe
CA2905509A1 (en) * 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
CN103279964B (zh) * 2013-04-23 2015-10-28 浙江大学 一种基于prca的pet图像动态重建方法及系统
EA201690406A1 (ru) 2013-08-16 2016-08-31 Мемориал Слоун-Кеттеринг Кэнсэ Сентр Селективные ингибиторы grp94 и способы их применения
CA2923829A1 (en) 2013-09-10 2015-03-19 Synta Pharmaceuticals Corp. Targeted therapeutics
JP6497767B2 (ja) * 2013-12-16 2019-04-10 日本化薬株式会社 癌治療におけるｈｓｐ９０阻害剤の抗腫瘍効果を予測する方法
EP3086792B1 (en) * 2013-12-23 2022-10-12 Memorial Sloan-Kettering Cancer Center Methods and reagents for radiolabeling
EP2942629A1 (en) * 2014-05-08 2015-11-11 Universität Würzburg Predictive markers for successful cancer immunotherapy
CA2961499A1 (en) 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy
AU2016336351A1 (en) 2015-10-05 2018-05-10 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
JP6594570B2 (ja) 2017-03-20 2019-10-23 フォーマ セラピューティクス，インコーポレイテッド ピルビン酸キナーゼ（ｐｋｒ）活性化剤としてのピロロピロール組成物
JP2020534015A (ja) 2017-09-22 2020-11-26 ユニヴァーシティ オブ ワシントン 細胞分子のｉｎ ｓｉｔｕコンビナトリアル標識化
WO2020061255A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Activating pyruvate kinase r
WO2020061378A1 (en) 2018-09-19 2020-03-26 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
CA3115315A1 (en) 2018-10-15 2020-04-23 Anthony A. HYMAN Compounds for treatment of diseases and methods of screening therefor
CN113424064B (zh) 2019-02-08 2025-03-04 露点治疗公司 表征化合物的凝聚物缔合特征的方法及其用途
EP3969122A4 (en) * 2019-05-15 2024-01-17 Whitehead Institute For Biomedical Research METHODS OF CHARACTERIZATION AND METHODS OF USING AGENT-CONDENSATE INTERACTIONS
CN114729941A (zh) 2019-09-18 2022-07-08 露点治疗公司 筛选凝聚物相关特异性的方法及其用途
AU2020350763A1 (en) 2019-09-19 2022-04-07 Novo Nordisk Health Care Ag Pyruvate kinase R (PKR) activating compositions
JP7589935B2 (ja) * 2019-10-31 2024-11-26 キヤノンメディカルシステムズ株式会社 解析装置および解析プログラム
US20230357760A1 (en) * 2020-10-02 2023-11-09 The Trustees Of Dartmouth College Method and agent for treating/preventing neurodegenerative disease and associated neuroinflammation and for evaluating putative prophylactics/therapeutics for treating/preventing neurodegenerative disease and neuroinflammation
US12128035B2 (en) 2021-03-19 2024-10-29 Novo Nordisk Health Care Ag Activating pyruvate kinase R
CN113025715A (zh) * 2021-03-23 2021-06-25 中山大学附属第一医院 Hop在预测胃癌预后中的应用
WO2024229406A1 (en) 2023-05-04 2024-11-07 Revolution Medicines, Inc. Combination therapy for a ras related disease or disorder
CN116813622A (zh) * 2023-05-19 2023-09-29 中国科学院基础医学与肿瘤研究所(筹) 一种基于分子伴侣hsp90介导的靶向降解gpx4的嵌合体及其制备方法和应用
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
US20250154171A1 (en) 2023-10-12 2025-05-15 Revolution Medicines, Inc. Ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7156111B2 (en) * 2001-07-16 2007-01-02 Akrion Technologies, Inc Megasonic cleaning using supersaturated cleaning solution
AU2002364566B2 (en) * 2001-12-12 2009-03-26 Conforma Therapeutics Corporation Assays and implements for determining and modulating HSP90 binding activity
US20040121971A1 (en) * 2002-12-20 2004-06-24 Gang Chen Therapeutic use of tumor necrosis factor-alpha mutein
US7959915B2 (en) * 2003-03-12 2011-06-14 Tufts University Inhibitors of extracellular Hsp90
EP1457499A1 (en) 2003-03-12 2004-09-15 Tufts University School Of Medicine Inhibitors of extracellular Hsp90
WO2005012482A2 (en) * 2003-06-30 2005-02-10 Sloan-Kettering Institute For Cancer Research Assay for identification of bioactive compounds that interact with heat shock protein 90
WO2005021552A1 (en) 2003-08-29 2005-03-10 Vernalis (Cambridge) Ltd Pyrimidothiophene compounds
GB0323810D0 (en) 2003-10-10 2003-11-12 Cancer Rec Tech Ltd Pyridothiophene compounds
AU2004286307A1 (en) * 2003-10-31 2005-05-12 Vitatex, Inc. Blood test prototypes and methods for the detection of circulating tumor and endothelial cells
US9403828B2 (en) * 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
US7834181B2 (en) 2005-02-01 2010-11-16 Slaon-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
RU2395090C2 (ru) * 2005-10-21 2010-07-20 БАЙЕР ХелсКер ЛЛСи Способы прогнозирования и предсказания рака и мониторинг терапии раковых заболеваний
DE102006023336A1 (de) 2006-05-18 2007-11-22 Merck Patent Gmbh 1,5-Diphenyl-pyrazole II
US8318790B2 (en) 2006-05-25 2012-11-27 Synta Pharmaceuticals Corp. Triazole compounds that modulate HSP90 activity
ES2645095T3 (es) 2006-06-30 2017-12-04 Sloan-Kettering Institute For Cancer Research Tratamiento de enfermedades neurodegenerativas a través de la inhibición de Hsp90
US8580519B2 (en) * 2006-11-27 2013-11-12 University Of Maryland, Baltimore Use of plasma HSP90 related to malignancy
CN101622350A (zh) * 2006-12-08 2010-01-06 奥斯瑞根公司 作为干预治疗靶标的miR-126调控基因和通路
KR20100016524A (ko) * 2007-04-13 2010-02-12 파마시클릭스, 인코포레이티드 히스톤 데아세틸라제의 억제제에 대한 약리효능 바이오마커로서의 칼슘 플럭스
EP2200653A2 (en) 2007-09-10 2010-06-30 University of Massachusetts Mitochondria-targeted anti-tumour agents
CN101918041A (zh) * 2007-10-12 2010-12-15 超分子有限公司 用于肿瘤诊断和治疗的氯毒素剂的系统性给药
RU2010128107A (ru) * 2007-12-07 2012-01-20 Байпар Сайенсиз, Инк. (Us) Лечение рака ингибиторами топоизомеразы в комбинации с ингибиторами parp
WO2009126310A2 (en) 2008-04-10 2009-10-15 Massachusetts Institute Of Technology Methods for identification and use of agents targeting cancer stem cells
WO2010020618A1 (en) * 2008-08-18 2010-02-25 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Susceptibility to hsp90-inhibitors
EP3205647B1 (en) * 2009-08-17 2020-05-13 Memorial Sloan-Kettering Cancer Center 2-(pyrimidin-5-yl)-thiopyrimidine derivatives as hsp70 and hsc70 modulators for the treatment of proliferative disorders
KR101906568B1 (ko) 2009-10-07 2018-10-10 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 저해제로서 유용한 퓨린 유도체
US20110118298A1 (en) * 2009-11-13 2011-05-19 Infinity Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cancer
US8710035B2 (en) 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
ES2647889T3 (es) 2011-04-05 2017-12-27 Sloan-Kettering Institute For Cancer Research Inhibidores de la Hsp90
KR102010222B1 (ko) 2011-04-05 2019-08-13 슬로안-케테링인스티튜트퍼캔서리서치 Ｈｓｐ９０ 억제제
WO2012149493A2 (en) 2011-04-28 2012-11-01 Sloan-Kettering Institute For Cancer Research Hsp90 combination therapy
KR102025142B1 (ko) 2011-07-08 2019-09-26 슬로안-케테링인스티튜트퍼캔서리서치 표지된 ｈｓｐ90 억제제의 용도
CA2905509A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2015089402A1 (en) 2013-12-12 2015-06-18 The University Of Chicago Methods and compositions related to hsp90 inhibitors and breast cancer
CA2961499A1 (en) 2014-09-17 2016-03-24 Memorial Sloan Kettering Cancer Center Hsp90-targeted inflammation and infection imaging and therapy

Also Published As

Publication number Publication date
EP3208615A2 (en) 2017-08-23
DK2729806T3 (en) 2017-05-15
US20140242602A1 (en) 2014-08-28
NZ620634A (en) 2016-07-29
AU2012282905A8 (en) 2017-08-31
AU2012282905A1 (en) 2014-02-13
US20210138091A1 (en) 2021-05-13
CA2841069A1 (en) 2013-01-17
WO2013009657A1 (en) 2013-01-17
CN104081203A (zh) 2014-10-01
CN109374889B (zh) 2022-04-19
MX2014000292A (es) 2015-03-06
US20240058482A1 (en) 2024-02-22
JP2019194232A (ja) 2019-11-07
CA2841173A1 (en) 2013-06-17
CA2841173C (en) 2022-06-21
WO2013009655A2 (en) 2013-01-17
AU2012282905B2 (en) 2017-04-06
ES2766623T3 (es) 2020-06-12
EP3208615B1 (en) 2019-10-09
EP3709022A1 (en) 2020-09-16
MX2014000286A (es) 2015-03-06
HK1243175A1 (en) 2018-07-06
BR112014000445A2 (pt) 2017-06-27
CN104081206A (zh) 2014-10-01
KR20170042805A (ko) 2017-04-19
JP2014525908A (ja) 2014-10-02
AU2012282903A1 (en) 2014-02-13
US9555137B2 (en) 2017-01-31
EP2729806A1 (en) 2014-05-14
JP6054389B2 (ja) 2016-12-27
AU2017204369B2 (en) 2019-08-01
WO2013009655A3 (en) 2013-05-10
KR102025142B1 (ko) 2019-09-26
CN109374889A (zh) 2019-02-22
KR102138218B1 (ko) 2020-07-28
ES2624982T3 (es) 2017-07-18
JP6218147B2 (ja) 2017-10-25
CA2841069C (en) 2021-11-23
AU2017204369A1 (en) 2017-07-20
CN104081203B (zh) 2018-07-31
US11607465B2 (en) 2023-03-21
EP2729806A4 (en) 2015-04-01
JP2017121233A (ja) 2017-07-13
US20140294725A1 (en) 2014-10-02
AU2012282905B8 (en) 2017-08-31
EP3208615A3 (en) 2017-11-01
EP2729806B1 (en) 2017-02-22
CN104081206B (zh) 2017-06-09
KR20140075667A (ko) 2014-06-19
JP2014527620A (ja) 2014-10-16
EA201490230A1 (ru) 2014-06-30
JP6662759B2 (ja) 2020-03-11

Similar Documents

Publication Publication Date Title
MX2014000286A (es) Uso de inhibidores hsp90 etiquetados.
PH12014500122A1 (en) Inhibitors of bruton's tyrosine kinase
PH12017500918A1 (en) Antibodies against cd73 and uses thereof
CA2851316C (en) Genes and proteins for alkanoyl-coa synthesis
UA114901C2 (uk) Інгібітори асс та їх застосування
WO2012058592A3 (en) Non-antagonistic egfr-binding molecules and immunoconjugates thereof
MX2019004193A (es) Combinacion de anticuerpos anti-kir y anticuerpos anti-pd-1 para tratar cancer.
GB201020995D0 (en) Biological materials and uses thereof
IN2012DN03012A (es)
EP4295912A3 (en) Compounds and methods for kinase modulation, and indications therefor
NZ700823A (en) Antibodies against claudin 18.2 useful in cancer diagnosis
WO2013033609A3 (en) Methods and compositions for the treatment and diagnosis of cancer
HK1199100A1 (en) Methods and compositions for the treatment and diagnosis of colorectal cancer
TN2011000524A1 (en) Antibodies specific to cadherin -17
AU2011276193A8 (en) Bipyridyl derivatives useful for the treatment of kinase - induced diseases
MX356671B (es) Métodos para inhibir fucosilación de proteína in vivo utilizando análogos de fucosa.
MX2013011354A (es) Anticuerpos contra antigeno 1 asociado con riñon y sus fragmentos de union de antigeno.
WO2012138715A3 (en) Small molecule inhibitors of xbp1 splicing
MX2011008456A (es) Anticuerpos anti-mst1r y usos de los mismos.
EP3888671A3 (en) Protein formulations
EP2821487A4 (en) METHOD FOR DETERMINING THE PRESENCE OR ABSENCE OF CANCER CELLS FROM A HEPATOCELLULAR CARCINOMA AND DIRECTORY MARKERS AND KIT
WO2013040358A3 (en) Assays and compositions for detection of agr2
PH12013502597A1 (en) Pyrazole derivatives useful as aldosterone synthase inhibitors
BR112013026043A2 (pt) determinação de origem de tumor
WO2012019192A3 (en) Cell-permeable molecules as growth factor receptor antagonists

Legal Events

Date Code Title Description
FG Grant or registration